



Bodisen Biotech to Report Record 3rd Quarter Earnings on Wednesday November 3, 2004 After Market Close

Wednesday November 3, 10:24 am ET

NEW YORK--(BUSINESS WIRE)--Nov. 3, 2004--Bodisen Biotech, Inc., (stock symbol: BBOI, website: www.bodisen.com) announced today that the company is scheduled to release its 3rd quarter financial results ending September 30, 2004 on Wednesday, November 3, 2004, after market close. The company expects to report record financial results.

Bodisen Biotech, a Delaware corporation, is a profitable biotech company with proprietary technologies for developing, manufacturing and marketing environmentally friendly organic agricultural products for the Chinese markets.

Using proprietary technologies, Bodisen sells over 60 packaged products, broken down into 3 product categories: Organic Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's organic fertilizers can be absorbed by plants within 48 hours while enriching soil conditions without the damaging effects associated with chemical fertilizers.

About Bodisen Biotech, Inc.

Bodisen is headquartered in Shaanxi, China, an agricultural hub of China and the economic gateway to the western regions of China. The Bodisen brand is a highly respected organic brand in China. Its "green" products support the mandate of the Chinese national government to increase crop yields for the purpose of decreasing China's dependency on food imports. Bodisen's products enjoy brand recognition and a price premium over competitive brands in China. With distribution in 20 provinces and an expanding geographic footprint, Bodisen is well positioned to take advantage of the growing demand for organic bio agricultural products in China.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Contact:

Bodisen Biotech, Inc.
Investor Relations:
Stephen Johnson, 212-566-3503
info@bodisen.com

Source: Bodisen Biotech, Inc.